### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

# (19) World Intellectual Property Organization International Bureau



### 

(43) International Publication Date 24 June 2004 (24.06.2004)

PCT

## (10) International Publication Number WO 2004/052298 A2

(51) International Patent Classification7:

A61K

(21) International Application Number:

PCT/US2003/039067

(22) International Filing Date: 9 December 2003 (09.12.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/432,219

9 December 2002 (09.12.2002) US

(71) Applicant (for all designated States except US): ARIZONA BOARD OF REGENTS, a body corporate of the State of Arizona, acting for and on behalf of ARIZONA STATE UNIVERSITY [US/US]; Box 879209, Tempe, AZ 85287 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PETTIT, George, R. [US/US]; 6232 Bret Hills Drive, Paradise Valley, AZ 85253 (US). MELODY, Noeleen [IE/US]; 7032 East Indigo Street, Mesa, AZ 85207 (US). (74) Agent: ROSENFIELD, Susan, Stone; Fennemore Craig, 3003 North Central, Suite 2600, Phoenix, AZ 85012-2913 (US).

(81) Designated States (national): CA, JP, US.

(84) Designated States (regional): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

### Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations CA, JP, European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
- of inventorship (Rule 4.17(iv)) for US only

#### Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NARCISTATIN PRODRUGS



(57) Abstract: The present invention provides prodrugs derived from the sparingly soluble anticancer isocarbostyril narciclasine, a component of various Narcissus species, said prodrugs having potential for use against animal and human cancers. Also disclosed is an efficient procedure for the synthetic conversion of narciclasine to several more soluble cyclic phosphate compounds, including "narcistatin".

